Modern Management of Chronic Kidney Disease in T2MD: A Practical Overview for Primary Care Providers
Bibliographic record
Abstract
The development of chronic kidney disease (CKD) in patients with T2DM (CKD in T2DM) is a common and major comorbidity. Not only is it associated with progressive kidney disease and end-stage kidney disease (ESKD), it is also associated with very high risk for major adverse cardiovascular events (MACE) and heart failure (HF) events. CKD in T2DM is extremely costly from a health economic perspective; however, most importantly, it results in significant reductions in patient quality of life and survival. For several decades, there has been a lack of new therapeutic options to address residual cardiorenal risk. The traditional pillars of therapy include glycemic control with a HbA1C target of 6.5%, blood pressure control with a blood pressure target of less than 130 mmHg, and the use of renin angiotensin aldosterone inhibitors (RAASi). Recently, several options have emerged that can address residual kidney and cardiovascular risk in these patients, thereby providing organ protection. Importantly, these therapies are grounded in the foundation of solid randomized, controlled clinical trials and are now prevalent in the guidelines that inform the management of CKD in T2DM. The novel pillars for kidney and cardiovascular protection include sodium glucose luminal transported 2 inhibitors (SGLT2i) and finerenone, a non-steroidal mineralocorticoid receptor antagonist (nsMRA). This article highlights practical considerations of these pillars for primary care providers with a focus on kidney protection.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.008 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.002 |
| Science and technology studies | 0.003 | 0.001 |
| Scholarly communication | 0.004 | 0.003 |
| Open science | 0.002 | 0.004 |
| Research integrity | 0.005 | 0.009 |
| Insufficient payload (model declined to judge) | 0.012 | 0.003 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".